UTMD

Business Context and Reporting Period

Company: Utah Medical Products Inc. (UTMD)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: UTMD manufactures and markets specialty medical devices, including obstetrics, gynecology, neonatal, and blood pressure monitoring products. The company operates as a single segment with manufacturing and sales facilities in the U.S., Ireland, UK, Australia, and Canada.

Key Financial Metrics

Liquidity: The company maintains a debt-free balance sheet with a current ratio of 48.6 as of June 30, 2026.

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 14.3% in Q2 2026 and 12.3% in 1H 2026 compared to the prior year. This was primarily driven by the complete loss of sales to two major customers: PendoTECH (domestic OEM) and a former China distributor. Combined, these accounts represented $1,065 of the Q2 decline and $1,923 of the 1H decline.
• Margin Pressure: Gross profit margin contracted slightly in Q2 (55.8% vs 56.2%) due to tariffs on Filshie Clip System imports from Ireland and fixed manufacturing overhead costs not scaling down with lower volume. However, 1H 2026 gross margin improved to 58.2% due to a more favorable product mix excluding low-margin sales to the former China distributor.
• Operating Expenses: Operating income declined 17.1% in Q2. While intangible asset amortization ceased (saving $531 in Q2), this was offset by a $213 increase in U.S. litigation costs related to Filshie product liability lawsuits.
• Working Capital: Inventories increased by $1.1 million in 1H 2026, causing inventory turns to decline to 1.7, below management targets. Accounts receivable days increased slightly to 38 days.

Guidance, Outlook, and Risks

• Revenue Outlook: Management revised its full-year 2026 guidance downward. While the initial plan was to offset lost revenue with new biopharma OEM sales, new customer acquisition has been slower than expected. Management now projects a full-year sales decline of 10-13% compared to 2025.
• Litigation: Filshie clip product liability lawsuits remain unresolved. Litigation expenses for 2026 are now estimated to be less than $1.6 million, higher than the 2025 total of $1.355 million. Management expects 2H 2026 litigation costs to be lower than 1H 2026.
• Tariffs: Tariffs on Filshie devices imported from Ireland reduced gross margins by 0.6 percentage points in Q2. While the specific Section 122 tariff authority expired in July 2026, management notes potential risks from Section 301 tariffs or reciprocal tariffs from other countries.
• Capital Allocation: The company continues to return capital to shareholders. In 1H 2026, it paid $1.976 million in dividends and repurchased $0.206 million of stock. Management intends to continue dividends and opportunistic share repurchases.

Investor Verification Checklist

• Customer Concentration Risk: Verify the progress of new biopharma OEM sales intended to replace the $2.889 million in lost revenue from PendoTECH and the China distributor.
• Litigation Exposure: Monitor the status of the four remaining unresolved Filshie product liability cases and the trajectory of legal fees against the $1.6 million annual estimate.
• Inventory Levels: Assess the $1.1 million increase in inventory and the decline in inventory turns (1.7x) to ensure no obsolescence risks exist given the sales decline.
• Tariff Impact: Confirm that no new Section 301 tariffs are imposed on Irish-manufactured devices in 2H 2026, which could further compress margins.
• FX Sensitivity: Review the impact of foreign currency fluctuations on OUS sales, which comprised 39% of Q2 revenue, noting that constant currency sales were down 30.7% in Q2.